NovelStem International (OTCMKTS:NSTM – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.
Volatility & Risk
NovelStem International has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500.
Profitability
This table compares NovelStem International and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NovelStem International | N/A | -124.84% | 6,900.07% |
| HCW Biologics | -34.73% | -486.87% | -29.19% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NovelStem International | 0 | 0 | 0 | 0 | 0.00 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
HCW Biologics has a consensus price target of $5.00, indicating a potential upside of 141.55%. Given HCW Biologics’ stronger consensus rating and higher possible upside, analysts clearly believe HCW Biologics is more favorable than NovelStem International.
Earnings and Valuation
This table compares NovelStem International and HCW Biologics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NovelStem International | $10,000.00 | 67.58 | $2.38 million | $0.06 | 0.23 |
| HCW Biologics | $50,000.00 | 278.62 | -$7.96 million | ($9.46) | -0.22 |
NovelStem International has higher earnings, but lower revenue than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than NovelStem International, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
3.0% of HCW Biologics shares are owned by institutional investors. 13.6% of NovelStem International shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
NovelStem International beats HCW Biologics on 8 of the 14 factors compared between the two stocks.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.
